These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32050707)

  • 1. Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
    Zaytsev D; Girshova L; Ivanov V; Budaeva I; Motorin D; Badaev R; Mirolubova J; Grobovenko E; Chitanava T; Zaykova E; Alexeeva J; Zaritskey A
    Biology (Basel); 2020 Feb; 9(2):. PubMed ID: 32050707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
    Niktoreh N; Lerius B; Zimmermann M; Gruhn B; Escherich G; Bourquin JP; Dworzak M; Sramkova L; Rossig C; Creutzig U; Reinhardt D; Rasche M
    Haematologica; 2019 Jan; 104(1):120-127. PubMed ID: 30093401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
    Roboz GJ; Knovich MA; Bayer RL; Schuster MW; Seiter K; Powell BL; Woodruff RD; Silver RT; Frankel AE; Feldman EJ
    Leuk Lymphoma; 2002 Oct; 43(10):1951-5. PubMed ID: 12481890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
    Sievers EL
    Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
    Chowdhury S; Seropian S; Marks PW
    Am J Hematol; 2009 Sep; 84(9):599-600. PubMed ID: 19650144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
    Marcelletti JF; Sikic BI
    Cancer Chemother Pharmacol; 2023 Nov; 92(5):369-380. PubMed ID: 37603048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin for
    Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
    Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia.
    Fenton C; Perry CM
    BioDrugs; 2006; 20(2):137-9. PubMed ID: 16626170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia.
    Lang K; Menzin J; Earle CC; Mallick R
    Am J Health Syst Pharm; 2002 May; 59(10):941-8. PubMed ID: 12040733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
    Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
    Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.
    Laurino M; Loron S; Larcher MV; Fossard G; Elhamri M; Deloire A; Balsat M; Barraco F; Labussière H; Ducastelle S; Renault M; Wattel E; Heiblig M; Salles G; Thomas X
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020020. PubMed ID: 32395209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
    Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
    Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
    Fenton C; Perry CM
    Drugs; 2005; 65(16):2405-27. PubMed ID: 16266206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.